ArticleThe Journal of biological chemistry2005
Interferon induces NF-kappa B-inducing kinase/tumor necrosis factor receptor-associated factor-dependent NF-kappa B activation to promote cell survival.
Article in The Journal of biological chemistry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 74 citations in OpenAlex.
- Comparative analysis of isoproterenol- and lipopolysaccharide-mediated cytoprotective responses in the heart.American journal of physiology. Heart and circulatory physiology · 2025Article
- Article
- Hypoxia-Induced Inflammation in In Vitro Model of Human Blood-Brain Barrier: Modulatory Effects of the Olfactory Ensheathing Cell-Conditioned Medium.Molecular neurobiology · 2025Article
- Role of miRNA in Highly Pathogenic H5 Avian Influenza Virus Infection: An Emphasis on Cellular and Chicken Models.Viruses · 2024Review
- The Role of the NF-kB Pathway in Intracranial Aneurysms.Brain sciences · 2023Review
- IFNβ-InducedInternational journal of molecular sciences · 2022Article
- Review
- A new combination strategy to enhance apoptosis in cancer cells by using nanoparticles as biocompatible drug delivery carriers.Scientific reports · 2021Article
- First Insight into the Modulation of Noncanonical NF-κB Signaling Components by Poxviruses in Established Immune-Derived Cell Lines: An In Vitro Model of Ectromelia Virus Infection.Pathogens (Basel, Switzerland) · 2020Article
- Diverse effects of interferon alpha on the establishment and reversal of HIV latency.PLoS pathogens · 2020Article
- Manipulation of Non-canonical NF-κB Signaling by Non-oncogenic Viruses.Archivum immunologiae et therapiae experimentalis · 2019Review
- Up-regulation of microRNA-203 in influenza A virus infection inhibits viral replication by targeting DR1.Scientific reports · 2018Article
- Bone marrow-derived mesenchymal stem cells induced by inflammatory cytokines produce angiogenetic factors and promote prostate cancer growth.BMC cancer · 2017Article
- TNF superfamily cytokines in the promotion of Th9 differentiation and immunopathology.Seminars in immunopathology · 2017Review
- IQGAP2 is a novel interferon-alpha antiviral effector gene acting non-conventionally through the NF-κB pathway.Journal of hepatology · 2016Article
- Bortezomib sensitizes human glioblastoma cells to induction of apoptosis by type I interferons through NOXA expression and Mcl-1 cleavage.Biochemical and biophysical research communications · 2016Article
- Innate immune memory and homeostasis may be conferred through crosstalk between the TLR3 and TLR7 pathways.Science signaling · 2016Article
- A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases the risk of papillary thyroid carcinoma.Genetic testing and molecular biomarkers · 2015Article
- Article
- Cell migration to CXCL12 requires simultaneous IKKα and IKKβ-dependent NF-κB signaling.Biochimica et biophysica acta · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Type I interferons (IFNs) play critical roles in the host defense by modulating the expression of various genes via the IFN-dependent activation of signal transducers and activators of transcription and NF-kappaB (nuclear factor kappa B) transcription factors. Previous studies established that IFNalpha/beta activates NF-kappaB to promote cell survival through a phosphatidylinositol 3-kinase (PI3K)/Akt pathway, which involves serine phosphorylation and degradation of IkappaB alpha. We now describe a second pathway by which IFNs activate NF-kappaB that is independent of IkappaB degradation. This pathway involves NF-kappaB-inducing kinase (NIK) and the tumor necrosis factor receptor-associated factor-2 (TRAF2) and results in IFNalpha/beta-induced processing of the p100/NF-kappaB2 precursor into p52. IFNalpha/beta stimulates NF-kappaB DNA binding and NF-kappaB-dependent transcription. Whereas expression of NIK and TRAF2 constructs causes NF-kappaB activation, expression of dominant negative NIK and TRAF2 constructs blocks IFN-promoted NF-kappaB activation and IFN-stimulated kappaB-dependent transcription and IFNalpha/beta-induced processing of the p100/NF-kappaB2 precursor into p52. In contrast, PI3K does not mediate IFNalpha/beta-induced p100 processing, although PI3K is involved in the pathway resulting in IkappaB alpha degradation. Moreover, whereas IFN promotes cell survival in lymphoblastoid cells, expression of dominant negative NIK and TRAF2 constructs enhances IFN-induced apoptosis. Our results for the first time place NIK and TRAF2, previously shown to function in TNF signaling, within the IFN signal transduction pathway. Thus, IFN induces NF-kappaB activation to mediate IFN-dependent cell survival signals through a "canonical" pathway of IkappaB alpha proteolysis mediated by PI3K/Akt and a "noncanonical" pathway of p100 processing mediated by NIK/TRAF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.